Long-term Sustained Response to Lenalidomide after Clearance of Bone Marrow Blasts by Azacytidine in High-risk Myelodysplastic Syndromes with Del5q: A Case Report
Our observations suggest that further studies could explore the sequential use of azacytidine followed by lenalidomide after achieving BM blast clearance in patients with HR MDS with del(5q).
Authors
- Esther Natalie Olíva (ORCID: https://orcid.org/0000-0001-9238-5734)
- Valentina Gianfelici (ORCID: https://orcid.org/0000-0003-3326-091X)
- Marco Giovannini (ORCID: https://orcid.org/0000-0001-5183-8506)
- Paolo de Fabritiis (ORCID: https://orcid.org/0000-0002-1835-0581)
- Pasquale Niscola (ORCID: https://orcid.org/0000-0002-2226-6518)
- Carla Mazzone (ORCID: https://orcid.org/0000-0002-1633-8837)
Institutions
- ASL Roma (IT)
- Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT)
- St. Eugenio Hospital (IT)
Publication Details
- Journal
- Cardiovascular & Hematological Agents in Medicinal Chemistry
- Published
- 2025-02-13
- DOI
- https://doi.org/10.2174/0118715257341062250130103015
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00